Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study

doi:10.4252/wjsc.v17.i7.106579

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (655)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

249

Figures (1-1)

Tables (1-4)

Sum=350

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

135

Sum=192

Publishing Process of This Article

Item

Count

Browse

Download

Sum=92

Jul 26, 2025 (publication date) through Aug 5, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Stem Cells. Jul 26, 2025; 17(7): 106579
Published online Jul 26, 2025. doi: 10.4252/wjsc.v17.i7.106579

Table 3 Transplantation-related complications of hematologic diseases in patients in different age groups, n (%)

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
aGVHD	42 (53.2)	22 (61.1)	20 (46.5)	0.195
I	16 (20.3)	11 (30.6)	5 (11.6)	0.100¹
II	11 (13.9)	4 (11.1)	7 (16.3)
III	10 (12.7)	5 (13.9)	5 (11.6)
IV	5 (6.3)	2 (5.6)	3 (7.0)
cGVHD	8 (10.1)	3 (8.3)	5 (11.6)	0.721
Virus reactivation
CMV	22 (27.8)	11 (30.6)	11 (25.6)	0.623
EBV	4 (5.1)	3 (8.3)	1 (2.3)	0.326

¹The difference of I and II-IV between the two groups.

aGVHD: Acute graft-vs-host disease; cGVHD: Chronic graft-vs-host disease; CMV: Cytomegalovirus; EBV: Epstein-Barr virus.

Citation: Li XG, Wang RM, Chen W, Yao T, Chen F, Xu YF, Lang T. Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study. World J Stem Cells 2025; 17(7): 106579
URL: https://www.wjgnet.com/1948-0210/full/v17/i7/106579.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i7.106579